SAB Biotherapeutics (SABS) FCF Margin (2021 - 2024)
SAB Biotherapeutics (SABS) reported FCF Margin of 8358.96% for Q4 2024, down 392811.0% on a YoY basis from N/an in Q1 2024, and down 183.07% quarter-over-quarter from 2952.95% in Q2 2024.
SAB Biotherapeutics (SABS) FCF Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics has reported FCF Margin for 4 years, with the latest figure at 8358.96% in Q4 2024.
- For the quarter ending Q4 2024, FCF Margin fell 392811.0% year-over-year to 8358.96%; the trailing twelve-month figure through Dec 2024 stood at 2618.65% (down 148794.0% YoY), and the FY2024 full-year result was 2618.65%, down 148794.0% from the prior year.
- FCF Margin for Q4 2024 stood at 8358.96%, down from 2952.95% in the prior quarter.
- The five-year high for FCF Margin was 44.68% in Q1 2021, with the low at 8358.96% in Q4 2024.
- Historically, FCF Margin has averaged 1592.5% across 4 years, with a median of 222.78% in 2022.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 567563 bps — and 2024, when it soared 280238 bps.
- SAB Biotherapeutics' FCF Margin stood at 65.47% in 2021, then declined by 18 bps to 77.41% in 2022, then slumped by 5624 bps to 4430.85% in 2023, then plunged by 89 bps to 8358.96% in 2024.
- The last three FCF Margin figures came in at 8358.96% (Q4 2024), 2952.95% (Q2 2024), and 1151.74% (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8,358.96% |
| Jun 30, 2024 | -2,952.95% |
| Mar 31, 2024 | -1,151.74% |
| Dec 31, 2023 | -4,430.85% |
| Sep 30, 2023 | -414.49% |
| Jun 30, 2023 | -5,755.33% |
| Mar 31, 2023 | -279.99% |
| Dec 31, 2022 | -77.41% |
| Sep 30, 2022 | -222.78% |
| Jun 30, 2022 | -79.69% |
| Mar 31, 2022 | -92.31% |
| Dec 31, 2021 | -65.47% |
| Sep 30, 2021 | 3.88% |
| Jun 30, 2021 | -54.09% |
| Mar 31, 2021 | 44.68% |